Factor Xa Face-Off Apixaban vs Rivaroxaban in Non-valvular Atrial Fibrillation and Venous Thromboembolism
Date: Apr 29, 2026 12:00 PM - 01:00 PM
Fee
$0.00
CE Hours
1.00
CE Units
0.100
Registration closes on May 06, 2026 10:00 PM
Activity Type
- Knowledge
Target Audience(s)
- Pharmacist
Accreditation(s)
Accreditation Statement: Howard University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Factor Xa Face-Off Apixaban vs Rivaroxaban in Non-valvular Atrial Fibrillation and Venous Thromboembolism
Factor Xa Face-Off Apixaban vs Rivaroxaban in Non-valvular Atrial Fibrillation and Venous Thromboembolism
Objectives
- Describe the difference between thrombosis in NVAF vs. VTE and the role of factor Xa inhibition
- Explain the application of patient-specific selection and dosing in NVAF and VTE
- Explain evidence on apixaban vs. rivaroxaban for effectiveness and bleeding
- Identify common DOAC pitfalls and failure management
Speaker(s)/Author(s)
|
Glory Petnkeu, PharmD |
Date:
04/29/26
Time:
12:00 PM - 01:00 PM
CE Hours
1.00